Diabetes: Assessing the pipeline

Atherosclerosis Supplements

Volumn 7, Issue 1 SPEC. ISS., 2006, Pages 43-49

  Lebovitz, Harold ^a  

^a SUNY Downstate Medical Center   (United States)

Author keywords

Amylin; Cardiovascular complications; Endocannabinoid; GLP 1; Metabolic syndrome; PPAR; Type 2 diabetes

Indexed keywords

AMYLIN; EXENDIN 4; FIBRIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INSULIN; METFORMIN; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PRAMLINTIDE; PROTEIN KINASE C; RIMONABANT; RUBOXISTAURIN; SULFONYLUREA; TESAGLITAZAR; VILDAGLIPTIN;

ANXIETY DISORDER; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEPRESSION; DIABETIC RETINOPATHY; EDEMA; FLUID RETENTION; GLUCOSE METABOLISM; HUMAN; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 33645084234     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2006.01.007     Document Type: Article

References (48)

1. S. Haffner, S. Lehto, and T. Ronnemaa Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
2. S. Grundy, B. Brewer, and J. Cleeman Definition of metabolic syndrome. Report of the NHLBI/AHA conference on scientific issues related to definition Circulation 109 2004 433 438
3. D. Drucker Minireview: the glucagons-like peptides Endocrinology 142 2001 521 527
4. M. Nauck, E. Homberger, and E. Siegel Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses J Clin Endocrinol Metab 63 1986 492 498
5. T. Vilsboll, T. Krarup, C. Deacon, S. Madsbad, and J. Holst Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients Diabetes 50 2001 609 613
6. M. Nauck, D. Wollschlager, and J. Werner Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM Diabetologia 39 1996 1546 1553
7. M. Turton, D. O'Shea, and I. Gunn A role for glucagon-like peptide-1 in the central regulation of feeding Nature 379 1996 69 72
8. A. Edvell, and P. Lindstrom Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?) Endocrinology 140 1999 778 783
9. G. Xu, D. Stoffers, J. Habener, and S. Bonner-Weir Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 1999 2270 2276
10. M. Zander, S. Madsbad, J. Madsen, and J. Holst Effect of 6-week course of glucagon-like peptide-1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 359 2002 824 830
11. L. Kjems, J. Holst, A. Volund, and S. Madsbad The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects Diabetes 52 2003 380 386
12. J. Buse, R. Henry, and J. Han Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 27 2004 2628 2635
13. R. DeFronzo, R. Ratner, and J. Han Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 28 2005 1092 1100
14. D. Kendall, M. Riddle, and J. Rosenstock Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 28 2005 1083 1091
15. L. Blonde, J. Han, and S. Mac Exenatide (exendin-4) reduced A1C and weight over 82 weeks in overweight patients with type 2 diabetes American Diabetes Association Scientific Sessions 2005 [abstract 477-P]
16. R. Heine, L. van Gaal, and D. Johns Comparison of exenatide and insulin glargine in MET and SU-treated patients with type 2 diabetes: exenatide achieved equivalent glycemic control, with weight reduction and less nocturnal hypoglycaemia American Diabetes Association Scientific Sessions 2005 [abstract 9-OR]
17. O. Schmitz, B. Brock, and J. Rungby Amylin agonists: a novel approach in the treatment of diabetes Diabetes 53 Suppl 3 2004 S233 S238
18. P. Hollander, P. Levy, and M. Fineman Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial Diabetes Care 26 2003 784 790
19. D. Karl, Y. Wang, G. Lorenzi, and J. Freeman In an open-label, clinical study pramlintide lowered A1C, body weight and insulin use in patients with type 2 diabetes failing to achieve glycemic targets with insulin therapy American Diabetes Association Scientific Sessions 2005 [abstract 48-OR]
20. I. Chapman Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes Diabetologia 48 2005 838 848
21. E. Schlicker, and M. Kathmann Modulation of transmitter release via presynaptic cannabinoid receptors Trends Pharmacol Sci 22 2001 565 572
22. J. Harrold, J. Elliott, and P. King Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Res 952 2002 232 238
23. J.P. Despres, A. Golay, and L. Sjostrom Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia NEJM 353 20 2005 2121 2134
24. L. Van Gaal, A. Rissanen, and A. Scheen Effects of the cannbinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Lancet 365 2005 1389 1397
25. J.-P. Despres, A. Golay, and L. Sjostrom One-year treatment with rimonabant increases plasma adiponectin levels beyond weight loss: the RIO-Lipids trial American Diabetes Association Scientific Sessions 2005 [abstract 7-LB]
26. Scheen AJ. Rimonabant in patients with type 2 diabetes: results from the RIO-Diabetes Trial. American Diabetes Association Late Breaking Clinical Trials. Available at: http://webcasts.prous.com/ada2005/article.asp?CID=YY&CLID= 2&AID=85.
27. P. Escher, and W. Wahli Peroxisome proliferator-activated receptors: insight into multiple cellular functions Mutat Res 448 2000 121 138
28. M. Stumvoll, and H. Haring Glitazones: clinical effects and molecular mechanisms Ann Med 34 2002 217 224
29. C. Rubin, P. Mohideen, J. Ledeine, R. Belder, and F. Fiedorek Improvement of glycemic control with muraglitazar, a novel dual PPAR α/γ agonist, in combination with metformin in patients with type 2 diabetes: a double-blind, randomized, pioglitazone-controlled study American Diabetes Association Scientific Sessions 2005 [abstract 14-OR]
30. C. Rubin, P. Mohideen, J. Ledeine, R. Belder, and F. Fiedorek Attainment of A1C goals with muraglitazar, a novel dual PPAR α/γ agonist, in combination with metformin in patients with type 2 diabetes: a double-blind, randomized comparison with pioglitazone plus metformin American Diabetes Association Scientific Sessions 2005 [abstract 2113-PO]
31. P. Mohideen, V. De Pril, and C. Rubin Glycemic efficacy and safety of muraglitazar, a novel dual PPARalpha/gamma agonist, plus glyburide in patients with type 2 diabetes failing sulphonylurea monotherapy: a randomized, double-blind, placebo-controlled study American Diabetes Association Scientific Sessions 2005 [abstract 518-P]
32. J. Buse, C. Rubin, and R. Frederich Muraglitazar, a dual (alpha/gamma) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes Clin Ther 27 2005 1181 1195
33. Kendall DM, on behalf of the Muraglitazar Study Group. Muraglitazar, a dual α/γ PPAR activator. Effects on glycaemic control and dyslipidemia in patients with type 2 diabetes. Presented at American Diabetes Association 65th Annual Scientific Sessions. Late breaking clinical trials, June 12, 2005.
34. S.E. Nissen, K. Wolski, and E.J. Topol Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus JAMA 294 2005 2581 2586
35. B. Ahren, R. Gomis, E. Standl, D. Mills, and A. Schweizer Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes Diabetes Care 27 2004 287480
36. B. Goldstein, J. Rosenstock, D. Anzalone, C. Tou, and P. Ohman Tesaglitazar improves glucose and lipid abnormalities in patients with type 2 diabetes American Diabetes Association Scientific Sessions 2005 [abstract 83-OR]
37. B. Fagerberg, S. Edwards, and T. Halmos Improvements in postprandial lipid handling and glucose tolerance with tesaglitazar in insulin-resistant, nondiabetic patients European Association for the Study of Diabetes (EASD) 2005 [abstract 755]
38. B. Fagerberg, S. Edwards, and T. Halmos Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population Diabetologia 48 2005 1716 1725
39. H. Schuster, B. Fagerberg, and S. Edwards Tesaglitazar reduced the prevalence of metabolic syndrome and impaired fasting glucose in an insulin-resistant, non-diabetic population American Diabetes Association Scientific Sessions 2005 [abstract 615-P]
40. H. Schuster, B. Fagerberg, and S. Edwards Tesaglitazar improves apolipoprotein abnormalities in an insulin-resistant, non-diabetic population American Diabetes Association Scientific Sessions 2005 [abstract 972-P]
41. B. Fagerberg, S. Edwards, and T. Halmos Tesaglitazar improves postprandial lipid handling and glucose tolerance in an insulin-resistant, non-diabetic population American Diabetes Association Scientific Sessions 2005 [abstract 614-P]
42. D. Koya, and G.L. King Perspectives in diabetes: protein kinase C activation and the development of diabetic complications Diabetes 47 1998 859 866
43. K. Tuttle, G. Bakris, R. Toto, J. McGill, K. Hu, and P. Anderson Effect of ruboxistaurin on albuminuria and GFR in persons with type 2 diabetes and nephropathy American Diabetes Association Scientific Sessions 2005 [abstract 223-OR]
44. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C-beta inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005;54:2188-97.
45. A. Vinik, V. Bril, and P. Kempler Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial Clin Ther 27 2005 1164 1180
46. A. Ceriello New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy Diabetes Care 26 2003 1589 1596
47. S. Furukawa, T. Fujita, and M. Shimabukuro Increased oxidative stress in obesity and its impact on metabolic syndrome J Clin Invest 114 2004 1752 1761
48. J. Dormandy, B. Charbonnel, and D. Eckland Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289